Comparison · NCT04382755-sae
Group A (Active) vs Group B (Control): serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Group A (Active) vs Group B (Control): serious adverse events. Trial comparisons, record NCT04382755-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04382755-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.185 | 0.104 | 0.308 | wilson | |
| Risk in group 2 | 0.208 | 0.0924 | 0.405 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0231 | -0.236 | 0.146 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.889 | 0.34 | 2.32 | log | |
| Odds ratio, group 1 over group 2 | 0.864 | 0.26 | 2.87 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Group A (Active) than on Group B (Control) | 43.2 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Group A (Active) | Standard of Care (SoC) + subcutaneous Zilucoplan® + prophylactic antibiotics until 14 days after last Zilucoplan®~Zilucoplan®: 14 days of SC Zilucoplan® on top of standard of care + prophylactic antibiotics until 14 days after last Zilucoplan® | 10 | 54 | EG000 |
| Group 2 | Group B (Control) | Standard of Care (SoC) + 1 week of prophylactic antibiotics (or until hospital discharge, whichever comes first)~Placebo: standard of care treatment + 1 week of prophylactic antibiotics + 1 week of prophylactic antibiotics (or until hospital discharge, whichever comes first) | 5 | 24 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- All-cause mortality monitored for up to 22 weeks, serious adverse events monitored for up to 20 weeks and other adverse events monitored for up to 28 days.
Source ClinicalTrials.gov
Trial
- Title
- Zilucoplan® in Improving Oxygenation, Short-, Longterm Outcome of COVID19 Patients With Acute Hypoxic Respiratory Failure
- NCT number
- NCT04382755
- Phases
- PHASE2
- Conditions
- COVID-19
- Interventions
- Zilucoplan®, Placebo
- Lead sponsor
- University Hospital, Ghent
- Results first posted
- 2023-09-14
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04382755?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04382755-sae